Documents

Neuralstem+Corporate+Presentation+website_October+2014

Description
the leader in stem cell
Categories
Published
of 32
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
Share
Transcript
  World Leader in Neural Stem Cell Science Corporate Overview October 2014  SafeHarborstatementsunderthePrivateSecuritiesLitigationReformActof1995:Thispresentationcontainsforward-lookingstatementsasdefinedinSection27AoftheSecuritiesActof1933asamended,andsection21EoftheSecuritiesExchangeActof1934,asamended.Suchforward-lookingstatementsarebaseduponNeuralstem,Inc. ’smanagement’s currentexpectations,estimates,beliefs,assumptions,andprojectionsabout Neuralstem’s businessandindustry.Wordssuchas  “anticipates,”“expects,”“intends,”“plans,”“predicts,”  “believes,”“seeks,”“estimates,”“may,”“will,”“should,”“would,”“potential,”“continue,”  andvariationsofthesewords(ornegativesofthesewords)orsimilarexpressions,areintendedtoidentifyforward-lookingstatements.Inaddition,anystatementsthatrefertoexpectations,projections,orothercharacterizationsoffutureeventsorcircumstances,includinganyunderlyingassumptions,areforward-lookingstatements.Theseforward-lookingstatementsarenotguaranteesoffutureperformanceandaresubjecttocertainrisks,uncertainties,andassumptionsthataredifficulttopredict.Therefore,ouractualresultscoulddiffermateriallyandadverselyfromthoseexpressedinanyforward-lookingstatementsasaresultofvariousriskfactors.Theserisksanduncertaintiesincludetherisksassociatedwiththeeffectofchangingeconomicconditions,trendsintheproductsmarkets,variationsin Neuralstem’s cashflow,marketacceptancerisks,technicaldevelopmentrisksandotherriskfactorsdetailedin Neuralstem’s SecuritiesandExchangeCommissionfilings.ForlinkstoSECdocumentspleasevisitthe company’s Website:neuralstem.com . Safe Harbor  Overview Industry Firsts ã Inventor of human neural stem cell technology is Karl Johe, Ph.D., Chairman and Chief Scientific Officer, while at NIH ã First FDA-approved neural stem cell therapy trials for ALS & chronic spinal cord injury ã First-in-class hippocampal neurogenic small molecule drug portfolio Platform Technology ã Regionally specific, fully characterized CNS human neural stem cells, cGMP mnfr. ã Two programs: 1) cell therapy direct injection, brain and spinal cord, 2) neurogenic small molecule development screening ã 14 U.S. patents re-affirmed worldwide  – technology and product; 8 pending Small Molecule  – Lead Product: NSI-189 ãMedical markets include depression, traumatic brain injury, Alzheimer’s disease, PTSDãNovel “hippocampus builder” initially funded by DOD program, early mover advantageã FDA-approved Phase I safety proved ã Phase Ibdata results show significant and large treatment effects, across all depressive and cognitive measures, for duration of trial ã Multiple Phase II trial-ready hippocampus-atrophy applications Cell Therapy  – Lead Product: NSI-566 ã Unmet medical needs include ALS, spinal cord injury, stroke ã FDA Phase I safety approval of cells and surgical device ã Data shows signs of efficacy; definitive evidence of long-term cell survival ã FDA-approved ALS Phase II; FDA-approved cSCIPhase I ã World-class collaborators3  12-Month Clinical Trial Catalysts NSI-566/ALS ã Phase II/III U.S. Trial ã FDA-approved Phase II trials concluded final surgeries July 2014 ã Data 6 mos. after final surgery ã NIH-major funding ã Increased dosing, all cervical ã Orphan Status Designation ã Est. 30,000 ALS patients, est. 5,600 diagnosed per year, U.S. ã Phase I/II Mexico City Trial ã In development ã  Accelerated timeline NSI-566/Chronic Spinal Cord Injury ã Phase I U.S. Trial ã FDA-approved Phase I trial commenced surgeries September 2014 ã Same cells, similar procedure as ALS ã One-year timeline goal ã Est. 840K SCI patients, 10K+ new SCI injuries per year, U.S. ã Phase I/II Seoul Trial ã  Acute SCI patients ã IND expected 2014 NSI-566/Ischemic Stroke (NeuralstemChina) ã Phase I/II China Trial ã World-class BaYiBrain Hospital ã Same cells, injected in brain ã Phase I-determine max safe dose, up to 18 Patients, treatments commenced December 2013 ã Phase II-100 patients, efficacy ã China stroke pop est: 1.75+ million NSI-189/ Major Depressive Disorder ã Phase II U.S. Trial ã Phase Ibdata results showed clinically meaningful improve-mentacross all depressive and cognitive measures ã Results continued for 8 weeks post-trial, despite fact of no drug accumulation in patients’ systems ã Est. 14.8 million MDD patients, U.S. ã NSI-189 proven safe in Iahealthy volunteers and IbMDD patient trials; add’l applications expected to commence testing at Phase II 4
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks